{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:49:18Z","timestamp":1782449358094,"version":"3.54.5"},"reference-count":27,"publisher":"Wiley","issue":"15","license":[{"start":{"date-parts":[[2011,12,2]],"date-time":"2011-12-02T00:00:00Z","timestamp":1322784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Multiple observational studies have suggested that breast cancer gene (<jats:italic>BRCA<\/jats:italic>)\u2010associated ovarian cancers have improved survival compared with <jats:italic>BRCA<\/jats:italic>\u2010negative ovarian cancers. However, most of those studies combined <jats:italic>BRCA1<\/jats:italic> and <jats:italic>BRCA2<\/jats:italic> patients or evaluated only <jats:italic>BRCA1<\/jats:italic> patients. The objective of the current study was to examine whether <jats:italic>BRCA1<\/jats:italic>\u2010associated and <jats:italic>BRCA2<\/jats:italic>\u2010associated ovarian cancers were associated with different outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>This was a single\u2010institution, retrospective analysis of patients who had a new diagnosis of histologically confirmed stage III or IV serous ovarian, fallopian tube, or primary peritoneal cancer between January 1, 1996 and February 1, 2011 and who underwent <jats:italic>BRCA<\/jats:italic> mutation testing on 1 of 2 institutional review board\u2010approved follow\u2010up studies. Patients who had been tested for <jats:italic>BRCA<\/jats:italic> mutations beyond 24 months of diagnosis were excluded from analysis to minimize selection bias from including patients who were referred for genetic testing because of long survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Data from 190 patients (143 <jats:italic>BRCA<\/jats:italic>\u2010negative patients, 30 <jats:italic>BRCA1<\/jats:italic>\u2010positive patients, and 17 <jats:italic>BRCA2<\/jats:italic>\u2010positive patients) were analyzed. During the study period, 73 deaths were observed (60 <jats:italic>BRCA<\/jats:italic>\u2010negative patients, 10 <jats:italic>BRCA1<\/jats:italic>\u2010positive patients, 3 <jats:italic>BRCA2<\/jats:italic>\u2010positive patients). The median follow\u2010up for the remaining 117 survivors was 2.5 years. At 3 years, 69.4%, 90.7%, and 100% of <jats:italic>BRCA<\/jats:italic>\u2010negative patients, <jats:italic>BRCA1<\/jats:italic>\u2010positive patients, and <jats:italic>BRCA2<\/jats:italic>\u2010positive patients were alive, respectively. On univariate analysis, age, <jats:italic>BRCA2<\/jats:italic> mutations, debulking status, and type of first\u2010line therapy (intravenous or intraperitoneal) were significant predictors of overall survival. On multivariate analysis, <jats:italic>BRCA2<\/jats:italic> mutations (hazard ratio, 0.20; 95% confidence interval, 0.06\u20100.65; <jats:italic>P<\/jats:italic> = .007), but not <jats:italic>BRCA1<\/jats:italic> mutations (hazard ratio, 0.70; 95% confidence interval, 0.36\u20101.38; <jats:italic>P<\/jats:italic> = .31), predicted for improved overall survival compared with <jats:italic>BRCA<\/jats:italic>\u2010negative patients. When carriers of <jats:italic>BRCA2<\/jats:italic> mutations were directly compared with carriers of <jats:italic>BRCA1<\/jats:italic> mutations, <jats:italic>BRCA2<\/jats:italic> mutations appeared to confer improved overall survival (hazard ratio, 0.29; 95% confidence interval, 0.08\u20101.05; <jats:italic>P<\/jats:italic> = .060), although this finding did not reach significance.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>The current data suggests that <jats:italic>BRCA2<\/jats:italic> mutations confer an overall survival advantage compared with either being <jats:italic>BRCA<\/jats:italic>\u2010negative or having a <jats:italic>BRCA1<\/jats:italic> mutation in high\u2010grade serous ovarian cancer. This finding may have important implications for clinical trial design. Cancer 2012. \u00a9 2011 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.26655","type":"journal-article","created":{"date-parts":[[2011,12,3]],"date-time":"2011-12-03T10:42:46Z","timestamp":1322908966000},"page":"3703-3709","source":"Crossref","is-referenced-by-count":74,"title":["Improved survival for <i>BRCA2<\/i>\u2010associated serous ovarian cancer compared with both <i>BRCA<\/i>\u2010negative and <i>BRCA1<\/i>\u2010associated serous ovarian cancer"],"prefix":"10.1002","volume":"118","author":[{"given":"David M.","family":"Hyman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Iasonos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel N.","family":"Grisham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela G.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary F.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas A.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Offit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard R.","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Spriggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah D.","family":"Kauff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,12,2]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20006"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21536"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/318787"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-17"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.18.1365"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/301749"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.1066"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02347-3"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.17.2260"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.13.990"},{"key":"e_1_2_6_12_2","first-page":"235","article-title":"Clinical features of ovarian cancer in Japanese women with germ\u2010line mutations of BRCA1","volume":"4","author":"Aida H","year":"1998","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.2.463"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11310"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.6905"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq577"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-006-9112-x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199611073351901"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.1703"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature10166"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1260"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.11.710"},{"key":"e_1_2_6_23_2","volume-title":"Applied Linear Regression Models","author":"Kutner MH","year":"2004"},{"key":"e_1_2_6_24_2","first-page":"921","article-title":"Relative frequency of primary ovarian neoplasms: a 10\u2010year review","volume":"74","author":"Koonings PP","year":"1989","journal-title":"Obstet Gynecol"},{"issue":"7","key":"e_1_2_6_25_2","article-title":"First\u2010in\u2010human trial of a poly(ADP\u2010ribose) polymerase (PARP) inhibitor MK\u20104827 in advanced cancer patients (pts) with antitumor activity in BRCA\u2010deficient and sporadic ovarian cancers [abstract]","volume":"28","author":"Sandhu SK","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0900212"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.2997"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.26655","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.26655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:58:29Z","timestamp":1760277509000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.26655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,2]]},"references-count":27,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1002\/cncr.26655"],"URL":"https:\/\/doi.org\/10.1002\/cncr.26655","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,2]]}}}